gvtcx

ERT Medicines

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Statuscomplete
Category (CPV) 33600000
RegionScotland
Procedurelimited
OCIDocds-h6vhtk-03cef8

Award

SupplierValueDateStatus
Aventis Pharma Ltd Trading As Sanofi · · active

description

Supply of ERT medicines to NHS Scotland:

NP92615 (a) Laronidase - Aldurazyme® NP92615 (b) Imiglucerase - Cerezyme® NP92615 (c) Agalsidase Beta - Fabrazyme® NP92615 (d) Alglucosidase Alfa - Myozyme®

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
24 May 2023 Voluntary ex-ante transparency (F15) Earlier regulations 014763-2023

more from The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.